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Abstract
Background: There is a large body of evidence which suggests that bile acids increase the risk of
colon cancer and act as tumor promoters, however, the mechanism(s) of bile acids mediated
tumorigenesis is not clear. Previously we showed that deoxycholic acid (DCA), a tumorogenic bile
acid, and ursodeoxycholic acid (UDCA), a putative chemopreventive agent, exhibited distinct
biological effects, yet appeared to act on some of the same signaling molecules. The present study
was carried out to determine whether there is overlap in signaling pathways activated by
tumorogenic bile acid DCA and chemopreventive bile acid UDCA.
Methods: To determine whether there was an overlap in activation of signaling pathways by DCA
and UDCA, we mutagenized HCT116 cells and then isolated cell lines resistant to UDCA induced
growth arrest. These lines were then tested for their response to DCA induced apoptosis.
Results: We found that a majority of the cell lines resistant to UDCA-induced growth arrest were
also resistant to DCA-induced apoptosis, implying an overlap in DCA and UDCA mediated
signaling. Moreover, the cell lines which were the most resistant to DCA-induced apoptosis also
exhibited a greater capacity for anchorage independent growth.
Conclusion: We conclude that UDCA and DCA have overlapping signaling activities and that
disregulation of these pathways can lead to a more advanced neoplastic phenotype.
Background
Bile acids are polar derivatives of cholesterol which are
synthesized in the liver and stored in the gall bladder [1].
During digestion bile is excreted into the intestinal tract
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where bile acids aid in the absorption of dietary fats.
Although the majority of the bile acids is reabsorbed and
reused a small fraction (1–4%) is not reabsorbed and
passes into the colon [2]. Here the primary bile acids,
those bile acids that are produced in the liver, are modi-
fied by enteric bacteria dehydroxylating the cholesterol
core and removing the conjugated amino acid to produce
unconjugated secondary bile acids. These secondary bile
acids, principally deoxycholic acid, have been associated
with increased risk for colon cancer
Epidemiological and animal model studies support the
concept that bile acids may play a role in the development
of colon cancer. Studies of populations that eat high fat
diets which promote more bile acid production show
increased risk for colon cancer [3,4] and patients diag-
nosed with colon cancer have elevated levels of serum bile
acids, especially deoxycholic acid (DCA) [3,5]. In studies
using animal models DCA was found to act synergistically
with carcinogens to increase colon tumorigenesis [6,7]
and could cause transformation of cells in vitro [8]. Col-
lectively these observations suggest that DCA may be a
tumor promoter. However it should be noted that not all
bile acids act to promote colon tumor development. Urso-
deoxycholic acid (UDCA) suppresses the development of
colon tumors in AOM-treated rats [9,10] and two studies
in human subjects suggest that UDCA can reduce the risk
of developing colorectal cancer [11-13]. Hence, in spite of
having very similar chemical structures, these two bile
acids have very distinct biological activities both at the
organismal level as well as in vitro [14]. To date the mech-
anism that accounts for this difference in function is not
clear.
The mechanism through which bile acids bring about
there biological effects is not well understood, however,
there is a growing body of evidence indicating that bile
acids can regulate gene expression [15-18]. DCA has been
shown to activate a number of mitogenic and apoptosis
associated signaling pathways which is consonant with its
proposed tumor promoting abilities including the epider-
mal growth factor receptor and the raf/mek/erk pathway
[19-21], protein kinase C [22-24], the AP-1 transcription
factor [25-27], and Cox2 [17] all of which are known to
be dysregulated during colon tumorigenesis. Much less is
known about the signaling mechanisms activated by
UDCA. However, in general UDCA displays activities that
are in opposition to those exhibited by DCA. For instance
UDCA can suppress activation of ras, EGFR-raf/mek/erk
pathway and AP-1 [19] and is cytoprotective as opposed
to cytotoxic DCA [28,29]. Similarly, while DCA interferes
with functioning of the p53 tumor suppressor, UDCA
does not [21]. Interestingly, we found that bile acids are
not readily taken up by colonic cells [30], but instead ini-
tiate intracellular signaling by their action at cell mem-
brane [22] in ligand independent manner possibly
through specialized domains like caveolae [31]. Given the
mode of action of DCA and UDCA on cell membranes, it
is likely that these two bile acids can act on some of the
same signaling pathways.
Understanding if DCA and UDCA utilize same pathways
to bring about diametrically opposed biological outcome
is very important in characterizing the role bile acids play
in tumorigenesis. In addition, before therapeutically tar-
geting DCA activated signaling to overcome the DCA
mediated colon carcinogenesis, it is important to address
whether UDCA employs similar signaling pathways as
DCA. In order to gain insight into overlap in signaling
pathways activated by DCA and UDCA, we isolated cell
lines resistant to UDCA induced growth arrest and then
tested these for their response to DCA induced apoptosis,
since, the most significant biological effects for DCA and
UDCA have been shown to be apoptosis and growth
arrest, respectively. Characterization of these resistant
cells demonstrated that some were also cross resistance to
the effects of DCA suggesting that DCA and UDCA signal-
ing activity may overlap. Importantly, we found evidence
that resistance to some DCA-activated signaling lead to a
more neoplastic phenotype. The relevance of these find-
ing to colon cancer are discussed.
Methods
Reagents
DCA, cholic acid, and hyoDCA were obtained from Sigma
Chemical (St. Louis, MO) and UDCA from Calbiochem
(La Jolla, CA). All were maintained as 100 mM stock solu-
tions in water. Upon addition of bile acids to media, no
change in pH was observed. Etoposide, cisplatin, and
adriomyosin were all obtained from Sigma Chemical Co.
(St. Louis, MO)
Cell culture
The HCT116 colon cancer cell line was used as the paren-
tal cell line in all experiments and was purchased from the
American Type Culture Collection (Rockville, Maryland).
All cell lines were propagated at 37°C and 5% CO2 in a
humidified atmosphere in Dulbecco's modified Eagle's
medium (DMEM) (Gibco/BRL, Gaithersburg/MD) sup-
plemented with 10% fetal bovine serum (Gibco/BRL),
100 units of penicillin, 100 mg of streptomycin, 2 mM L-
glutamine, 4 mM sodium pyruvate and 100 μM non-
essential amino acids.
Derivation of UDCA resistant cell lines
Parental HCT116 cells were plated onto a 162 cm2 flask
with 50 milliliters of fresh DMEM and allowed to attach
and grow for 24 hours. This produced a cell monolayer
that was approximately 40% confluent. These cells were
mutagenized by incubation with ethyl methane sulfonateBMC Cancer 2006, 6:219 http://www.biomedcentral.com/1471-2407/6/219
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(Sigma) at a final concentration of 500 μg/ml for 12
hours. Cells were then rinsed three times with DMEM, re-
fed with fresh DMEM before returning to the incubator for
24 hours. Cells were then split into 20 ten centimeter
dishes and allowed to grow for 24 hours prior to the addi-
tion of UDCA to a final concentration of 500 μM in each
dish. Cells were refed with fresh DMEM supplemented
with 500 μM UDCA once a week for four weeks at which
time colonies of UDCA resistant cells appeared. From this
treatment 47 UDCA resistant colonies emerged, 41 of
which were successfully expanded into peremanent cell
lines. Once the lines were expanded into 10 cm dishes,
cells were maintained in DMEM supplemented with 250
μM UDCA. These lines were designated HOMUR cells for
HCT116 Odd Morphology UDCA resistant.
Screening HOMUR lines for cross resistance to DCA and 
hyoDCA
HOMUR cells were plated at 100,000 cells per 35 mm
dish and then incubated for 24 hours prior to the addition
of either DCA or hyoDCA to a final concentration of 500
μM. Cells exposed to DCA were incubated for 24 hours
and then harvested and the fraction of cells undergoing
apoptosis determined as described below. HOMUR cells
exposed to hyoDCA were incubated for 48 hours with this
bile acid and then the fraction of apoptotic cells deter-
mined.
Apoptosis assay
For apoptosis assays 100,000 HCT116 cells were plated
onto 60 mm tissue culture plates and allowed to attach for
24 hours. This procedure produced a cell monolayer that
was 30–40% confluent at the time bile acids were added.
The cells were treated with 500 μM bile acids for the times
indicated. The media were removed and saved and the
remaining attached cells rinsed in PBS and harvested by
trypsinization. The cell pellet was re-suspended in the
saved media. The number of apoptotic cells was then
quantitated by staining with acridine orange and ethid-
ium bromide as described previously [14].
Anchorage independent growth
To test for anchorage independent growth cells were
grown in 0.6% agarose as follows. A stock of 1.2% LMP
agarose (Gibco) was autoclaved and then the solution
equilibrated at 37°C for 30 minutes. The LMP agarose was
diluted 1:1 with DMEM and one milliliter of the mixture
poured into each well of a 6 well plate to form a basal
layer. This basal layer was allowed to solidify for 10 min-
utes at 4°C prior to reequilibrating at room temperature
for 30 minutes. The top layer was similar to the basal
layer, but contained 5,000 cell per well. The top layer was
allowed to solidify at room temperature for approxi-
mately 15 minutes and the plates were then transferred to
a 37°C incubator with 5% CO2. The following day, one
milliliter of medium was added to each well, and the cells
refed every 3–4 days for 2.5 weeks. Three sets of experi-
ments were performed in triplicate. The total number of
colonies was counted and the percent colony formation
determined.
Statistical analysis
Statistical analysis of data was performed using Sigmastat
statistical analysis software. In all cases a p value of <0.05
was considered the threshhold for significance.
Results
Isolation and characterization of cells resistant to UDCA-
induced growth arrest
To test for overlap in signaling and elucidate the differ-
ences in signaling activated by DCA and UDCA each of
the HOMUR cell lines was tested for resistance to apopto-
sis induced by DCA and hyoDCA as described in the
Methods section (Figure 1A). These two bile acids were
selected because DCA is known to induce apoptosis, but
The majority of HOMUR cell lines exhibit resistance to  DCA-induced and hyoDCA-induced apoptosis Figure 1
The majority of HOMUR cell lines exhibit resistance 
to DCA-induced and hyoDCA-induced apoptosis. (A) 
HOMUR cells were incubated with 500 micromolar DCA for 
24 hours and the fraction of apoptotic cells determined as 
described in Methods. The apoptotic value for each of the 41 
HOMUR lines is depicted as a dot along a scale extending 
from 0 to 60% apoptosis. The extent of apoptosis obtained 
for parental HCT116 cells is indicated with an arrow at the 
right. Also on the right are dots representing individual 
HOMUR cell lines with apoptotic values greater than 60%. 
(B) HOMUR cells were incubated with 500 micromolar hyo-
DCA for 48 hours and the fraction of apoptotic cells deter-
mined as in panel A. Each dot represents a single HOMUR 
cell line and its placement is representative of the apoptotic 
value for that cell line. The apoptosis obtained using HCT116 
cells is indicated with an arrow at the right. In addition, 
HOMUR lines with apoptotic values greater than 40% are 
represented as dots to the right of the graph.BMC Cancer 2006, 6:219 http://www.biomedcentral.com/1471-2407/6/219
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has no ability to inhibit cell proliferation [14]. In contrast,
we found that hyoDCA initially causes growth arrest fol-
lowed by apoptosis in HCT116 cells (unpublished data).
Because hyoDCA exhibits biological activity that is inter-
mediate to DCA and UDCA we also examined the
HOMUR lines for resistance to the cytotoxicity of this bile
acid. When tested for cross resistance to these other bile
acids we found that the majority of HOMUR cell lines
demonstrated some resistance to apoptosis induced by
either DCA or HyoDCA. When tested for DCA-induced
apoptosis 88% (36 out of 41) of the HOMUR lines exhib-
ited reduced apoptosis compared to the 60% apoptosis
observed with parental HCT116 cells when treated with
DCA under the same conditions (Figure 1A). Indeed
apoptosis was virtually undetectable in one HOMUR line
(HOMUR 7) when incubated with 500 micromolar DCA
for 24 hours. The average percent DCA-induced apoptosis
for all of the resistant HOMUR lines was 18.9%, a reduc-
tion of ~32% relative to similarly treated parental
HCT116 cells. We found that 93% (38 out of 41) of the
HOMUR lines also exhibited reduced apoptosis induced
by hyoDCA when compared with the parental control val-
ues suggesting that HOMUR lines were also resistant to
the cytotoxic effects of this bile acid. The average percent
hyoDCA-induced apoptosis for the resistant HOMUR
lines was 10% a reduction of ~25% relative to parental
HCT116 cells. Moreover, the HOMUR 7 cells again
showed no evidence of apoptosis when treated with hyo-
DCA indicating that this line was resistant to apoptosis
induced by both bile acids. Interestingly, a small fraction,
12% (5 out of 41) for DCA and 5% (2 out of 41) for hyo-
DCA, of HOMUR lines showed increased apoptosis than
parental HCT116 cells when treated with these bile acids
suggesting that the mutations that made them resistant to
UDCA made them more sensitive to bile acid-induced
apoptosis. From these experiments we concluded that dis-
ruption of the pathways that enable UDCA to inhibit cell
growth can also lead to resistance to the cytotoxic effects
induced by other bile acids.
Resistant HOMUR cells also show resistance at the 
biochemical level
From our bank of HOMUR cells we selected three lines
representative for further study. HOMUR7 cells were
selected because of their profound resistance to DCA-
induced apoptosis. The HOMUR11 line was selected
because the bile acid-induced apoptosis for both DCA and
hyoDCA was close to the average value for bile acid-
induced apoptosis by the group of HOMUR cell lines as a
whole. The HOMUR17 line was selected because it was
one of a small fraction of HOMUR lines that were more
sensitive to bile acid-induced apoptosis than were the
parental cells. Hence, HOMUR 7, 11, and 17 represent the
spectrum of phenotypes present in our group of HOMUR
cell lines. To confirm that these cell lines were indeed
resistant to the growth arrest induced by UDCA growth
curves were generated in the presence and absence of 500
micromolar UDCA for the three HOMUR lines and com-
pared with parental HCT116 cells (Figure 2). As can be
seen UDCA completely suppresses proliferation of
HCT116 cells. However, all HOMUR lines were capable of
growth in UDCA. It should be noted that the HOMUR17
line undergoes apoptosis spontaneously at a relatively
high rate making it is difficult to obtain a growth curve
that accurately represents the amount of proliferation
exhibited by these cells. No such spontaneous apoptosis
has ever been exhibited by either of the other HOMUR cell
lines tested (data not shown). From these studies we con-
clude that the HOMUR cell lines are indeed resistant to
UDCA-induced growth arrest.
We next sought to confirm that the sensitivity/resistant
phenotype observed during screening of the HOMUR cell
lines was reproducible. Each of the HOMUR lines were
incubated with DCA or hyoDCA and apoptosis quanti-
tated (Figure 3). As can be seen the both the HOMUR7
and HOMUR11 cell lines exhibited significantly reduced
DCA and hyoDCA-induced apoptosis (p < 0.05 by t-test)
relative to parental HCT116 cells. Surprisingly,
HOMUR17s exhibited twice the level of hyoDCA-induced
apoptosis as compared with HCT116 cells (p < 0.05 by t-
test) consistent with our initial characterization of this
line as being more sensitive to hyoDCA-induced apopto-
sis.
We next asked whether the resistance to DCA-induced
apoptosis in HOMUR lines was reflected at the biochem-
ical level. Cleavage of poly ADP-ribose polymerase
(PARP) is well known to be associated with the onset of
apoptosis and so was chosen as a biochemical marker for
apoptotic cell death [32]. The three HOMUR lines and
HCT116 cells were incubated with 500 micromolar DCA
and harvested at various times after incubation. Western
blots of cell extracts were probed with anti-PARP (Figure
5). These experiments demonstrated that cleavage prod-
ucts of part are readily visible in HCT116 cells but are
either absent (HOMUR 7 cells) or reduced (HOMUR11
cells) in apoptosis resistant cell lines. We conclude that
cleavage of PARP is dramatically reduced in the most pro-
foundly resistant HOMUR 7 cell line.
Resistance to bile acids also confers a capacity for 
anchorage independent growth
We and others have previously postulated that resistance
to DCA-induced apoptosis may be important in neoplas-
tic transformation that leads to tumorigenesis in the colon
[14,33]. Because the HOMUR lines exhibit resistance to
bile acid-induced apoptosis we reasoned that they might
be used to test this hypothesis by examining their tumor-
igenic properties using anchorage independent growth asBMC Cancer 2006, 6:219 http://www.biomedcentral.com/1471-2407/6/219
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a measure of their neoplastic development. Conse-
quently, HCT116 cells and all three HOMUR lines were
characterized for growth in soft agar (Figure 5). We found
that the HOMUR7 line was significantly more capable of
growing in soft agar than were any of the HOMUR lines or
parental HCT116 cells (p < 0.05 by t-test). Notably,
HOMUR17 cells which are more sensitive to DCA-
induced apoptosis, showed significantly reduced soft agar
growth capacity (p < 0.05 by t-test). Since anchorage inde-
pendent growth was exhibited by the DCA-resistant line
and not by the sensitive line we concluded that resistance
to DCA-induced apoptosis correlated with anchorage
independent growth.
We next asked whether resistance to bile acid-induced
apoptosis could confer resistance to apoptosis induced by
other agents. To examine this we tested the three HOMUR
cell lines for sensitivity to apoptosis induced by three dif-
ferent commonly used anti-cancer agents, etoposide, cis-
platin, and adriamycin. From time course analysis using
HCT116 cells we determined that exposure to these agents
for 36 hours was required to induce substantial apoptosis
so each HOMUR cell line was exposed to the three agents
for 36 hours, harvested and the fraction of apoptotic cells
determined (Figure 6). As can be seen the HOMUR7 line
was significantly less sensitive to all three agents (p < 0.05
by t-test). HOMUR11 cells, which are more sensitive to
Selected HOMUR cells show resistance to UDCA-induced growth arrest Figure 2
Selected HOMUR cells show resistance to UDCA-induced growth arrest. (A) HCT116, (B) HOMUR 7, (C) HOMUR 
11, or (D) HOMUR 17 cells were plated into 35 mm plates and allowed to attach for 48 hours. Subsequently the plates were 
either left untreated (closed circles) or 500 micromolar UDCA was added to the media (open circles) and incubation contin-
ued. Sample plates were removed at the time intervals indicated and the number of cells counted. Experiments were per-
formed in triplicate and the average values graphed. Error bars represent standard deviation.
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DCA-induced apoptosis when compared with
HOMUR7s, showed significant resistance to only two of
the drugs, etoposide and adriamycin. Interestingly, even
the bile acid-induced apoptosis sensitive HOMUR17 cells
exhibited some reduced sensitivity to cisplatin. From
these experiments we conclude that resistance to bile acid-
induced apoptosis can also confer resistance to other
apoptosis-inducing agents.
Discussion
In the present study we derived a set of cells that were
resistant to UDCA and then tested these cells for cross
resistance to the effects of two other bile acids to ascertain
whether there was overlap in the signaling pathways that
mediate bile acid-induced cell death. We were able to
demonstrate that there is an overlap in the signaling
mechanisms activated by UDCA which lead to growth
arrest and those activated by DCA which bring about
apoptosis. Careful examination of the number of UDCA-
induced growth arrest resistant cells revealed that the
majority of these lines also exhibited resistance to DCA-
induced apoptosis a finding that is consistent with the
concept that the signaling activities of these two bile acids
may overlap. Most of the HOMUR lines exhibited some
degree of resistance suggesting that the extent of overlap in
signaling activities may be extensive. Hence, it seems
likely that the signaling activities induced by bile acids
and which are responsible for growth arrest and for apop-
tosis may have much in common.
The likely extensive overlap in signaling activities between
DCA and UDCA raises the question of how these two bile
acids can exhibit such distinctly different biological activ-
ities. Considering that all bile acids have such similar
chemical structures it is not unexpected that they can also
activate many of the same intracellular signaling mecha-
nisms. However, there is also slight evidence that some
Apoptosis resistant HOMUR cells exhibit reduced PARP  cleavage when treated with DCA Figure 4
Apoptosis resistant HOMUR cells exhibit reduced 
PARP cleavage when treated with DCA. HCT116, 
HOMUR 7, HOMUR 11, or HOMUR 17 cells were plated 
onto 10 cm plates and allowed to attach for 48 hours. Cells 
were either untreated (-) or incubated with 500 micromolar 
DCA (+) and sample plates harvested at the indicated time 
intervals. Total cell proteins were extracted, fractionated by 
SDS-PAGE, and protein blots probed with antibodies against 
PARP. Alpha tubulin was used to control for loading varia-
tions. These experiments were repeated twice. Representa-
tive immunoblots are depicted.
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Selected HOMUR cells show resistance to DCA-induced and  hyoDCA-induced apoptosis Figure 3
Selected HOMUR cells show resistance to DCA-
induced and hyoDCA-induced apoptosis. HCT116, 
HOMUR 7, HOMUR 11, or HOMUR 17 cells were plated 
onto 60 mm plates and allowed to attach for 48 hours. Plates 
were then incubated either with (A) 500 micromolar DCA 
for 24 hours or (B) with 500 micromolar hyoDCA for 48 
hours. Apoptosis in each culture was quantitated as 
described in Methods. Bars represent the average of tripli-
cate results. Error bars represent standard deviation. 
Astrisks indicate a significant difference (p < 0.05) when com-
pared with parental HCT116 cells.
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bile acids interact with intracellular signaling in unique
ways. For example DCA can stimulate the EGFR/ras/mek/
erk signal transduction pathway, yet UDCA has been
shown to suppress this same pathway [19,21]. Hence,
although the same pathways may be targeted for modula-
tion by the different bile acids the effect that they have on
these pathways, activation or inhibition, may determine
the ultimate biological outcome of exposure to these
agents. This suggests that the distinction between tumor
promotion and prevention may be very subtle
These notions emphasize the importance of elucidating
the identity and the nature of the unique signaling mech-
anisms activated by DCA and UDCA. Insight into the
characteristics of these pathways can be gleaned from our
characterization of the HOMUR cells. Our observation
that only the most profoundly DCA resistant HOMUR 7
line exhibits extensive growth in soft agar supports the
notion that resistance to DCA-induced apoptosis favors a
more tumorogenic phenotype. Our finding that HOMUR
7 cells are also markedly resistant to three commonly used
anti-cancer agents suggests that DCA-induced apoptosis
may utilize pathways that are also employed by cancer
therapeutics. Hence, profound resistance to DCA corre-
lates with acquired resistance to multiple other drugs each
of which is known to cause cell death through very differ-
ent mechanisms. Collectively these results suggest that
HOMUR cells that are resistant to DCA-induced apoptosis  exhibit anchorage independent growth Figure 5
HOMUR cells that are resistant to DCA-induced 
apoptosis exhibit anchorage independent growth. 
HCT116, Homur7, Homur11, and Homur17 cells were 
plated into six well trays in 0.6% LMP agarose as described in 
Methods and the cells allowed to grow for 2.5 weeks. Colo-
nies were then stained and counted. Bars depict the average 
number of clones per well from four independent experi-
ments done in triplicate +/- standard deviation. Asterisks 
indicate a significant difference (p < 0.05) when compared 
with parental HCT116 cells.
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HOMUR cells that are resistant to DCA-induced apoptosis exhibit resistance to other anti-cancer agents Figure 6
HOMUR cells that are resistant to DCA-induced apoptosis exhibit resistance to other anti-cancer agents. 
Parental HCT116 cells and HOMUR 7, 11, and 17 cells were plated at a density of 100,000 cells per 35 mm plate and incubated 
at 37°C for 48 hours. Subsequently etoposide (panel A) was added to a final concentration of 50 μM, cisplatin (panel B) added 
to a final concentration of 50 μM, or adriamycin (panel C) added to a final concentration of 1 μM to the plates. The cells were 
incubated with the drugs for 36 hours and then the number of apoptotic cells quantitated as described in Methods. The bars 
represent average values of three replicates. Error bars depict standard deviation. Astrisks denote a significant difference (p < 
0.05) when compared with parental HCT116 cells.
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resistance to bile acid-induced apoptosis is tumorigeneic
and is consistent with findings made using natural human
tumors [33].
Conclusion
Our results strongly suggest that there is overlap in the sig-
naling activated by DCA and UDCA. However, there is
also evidence that these two bile acids may activate
unique signaling pathways that may account for their dia-
metrically opposed biological effects. Importantly, we
show that resistance to DCA induced apoptosis confers a
more neoplastic phenotype on tumor cells. Our results
also have therapeutic implications as targeting of bile acid
pathways may have unexpected consequences unless they
are adequately understood.
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